CFAP410

Across TCGA pan-cancer cohorts, CFAP410 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CFAP410 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher CFAP410 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP410 expression acts as an unfavorable survival marker.

UCS, BLCA, and KIRP are the cancer types where CFAP410 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.001	0.690	<.001	36	view →
BLCA	OS	Median	All	0.228	0.720	.010	18	view →
KIRP	OS	Median	All	0.135	0.703	.002	6	view →
LIHC	DFS	Median	All	0.096	0.526	.042	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CFAP410–UCS (OS)

Open the UCS breakdown →